Exiqon Expands in US; Sales Headquarters Established
Complete the form below to unlock access to ALL audio articles.
Exiqon A/S has announced it is expanding its US presence by opening a sales, distribution and technical support facility in the heart of the Boston, MA biotech community.
The entity, Exiqon, Inc., is already operational and is being managed by Michael Kallelis, who serves as President. The offices are located just north of Boston in Woburn, MA.
"As our miRCURY™ LNA brand of microRNA research products continue to rapidly grow, we want to bring distribution, technical support and sales specialists closer to our US customers," said Michael Kallelis, President of Exiqon, Inc.
"We will be able to provide excellent customer support and faster order fulfillment as our sales continue to expand."
"We also offer a microRNA profiling service for researchers that do not want to carry out these experiments themselves," he added.
Kallelis continued, "As more customers discover the advantages of our miRCURY™ LNA microarrays, an experienced sales force in the US will further enhance our market awareness and is an essential element for customer satisfaction and continued growth."
Establishing a US presence will also liberate resources at the existing Danish facility to focus on sales opportunities in Europe and Asia, where a distributor network is being put in place.
The significance of microRNA in gene expression continues to be published in a growing number of scientific journals.
Exiqon’s proprietary LNA™ technology, which forms the basis of the miRCURY™ LNA product line, is suited for microRNA research products and several miRCURY™ LNA products are the de facto standard for microRNA researchers.
In July, the company announced it had secured the right to use over 200 human and viral microRNA sequences in diagnostic applications, through two separate co-exclusive license agreements with The Rockefeller University and Garching Innovation, the technology transfer agency of the Max Planck Society.
The licenses allow Exiqon to expand into the development of diagnostic products.
